Pursuant to the Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform that, the Company has announced the launch of its next-generation 20-valent Pneumococcal Polysaccharide Conjugate Vaccine (Adsorbed) I.P., 20 Valent (PCV20) for adults in India, on August 11, 2025.
PFIZER · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Pfizer Limited has launched its next-generation 20-valent Pneumococcal Conjugate Vaccine (PCV20) for adults in India on August 11, 2025. The vaccine is approved for adults aged 18 years and older and offers protection against 20 serotypes of pneumococcal disease, which is broader than any other conjugate vaccine previously available in India. It is administered as a single shot, eliminating the need for a second dose. The launch targets the domestic Indian market and addresses the growing need for adult immunization, particularly for people over 50 and those with chronic conditions such as asthma, COPD, kidney disease, and diabetes.
This product launch strengthens Pfizer's preventive healthcare portfolio in India and could add a new revenue stream in the adult vaccines segment. It is a positive development for the company as it expands its addressable market, though near-term impact on earnings will depend on adoption rates and pricing.